| 0 (0%) | 09-27 09:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.15 |
1-year : | 17.19 |
| Resists | First : | 10.4 |
Second : | 14.72 |
| Pivot price | 13.12 |
|||
| Supports | First : | 3.42 |
Second : | 2.84 |
| MAs | MA(5) : | 11.47 |
MA(20) : | 13.26 |
| MA(100) : | 14.13 |
MA(250) : | 13.82  |
|
| MACD | MACD : | -0.9 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 25.4 |
D(3) : | 30.1 |
| RSI | RSI(14): 16 |
|||
| 52-week | High : | 18.79 | Low : | 2.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NLTX ] has closed below the lower bollinger band by 42.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NLTX ] is to continue within current trading range. It is unclear right now based on current values. 266.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.59 - 3.61 | 3.61 - 3.62 |
| Low: | 3.38 - 3.4 | 3.4 - 3.41 |
| Close: | 3.46 - 3.49 | 3.49 - 3.52 |
Fri, 26 Sep 2025
Neoleukin Therapeutics (NASDAQ:NLTX) Shares Up 2.4% – Time to Buy? - Defense World
Fri, 26 Sep 2025
Neoleukin Therapeutics (NASDAQ:NLTX) Shares Up 2.4% - Time to Buy? - MarketBeat
Thu, 04 Sep 2025
Neoleukin Therapeutics (NASDAQ:NLTX) Shares Up 6.3% – Should You Buy? - Defense World
Tue, 25 Jul 2023
Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX | FinancialContent - FinancialContent
Tue, 23 May 2023
Biomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) - Yahoo Finance
Wed, 16 Nov 2022
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -12.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 34.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.8 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|